

Hui Shao M.D.,Ph.D.,MHA

Updated as of 2/7/2020

Current Address: 1225 Center Dr, Gainesville, FL 32610

Phone Number: (352)-294-8323

E-Mail: Hui.Shao@cop.ufl.edu

EDUCATION:

August 2012 ~ March 2017	PhD, Global Health Management and Policy <i>Tulane University, USA</i>
September 2010 ~ June 2012	MHA, Social Medicine and Health Administration <i>Shandong University, China</i>
September 2005 ~ June 2010	MD, general medicine <i>Shandong University, China</i>

PROFESSIONAL EXPERIENCES:

Aug 2019-present	Assistant Professor, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida
Oct 2017-present	Adjunct Professor, Department of Global Health Management and Policy, SPHTM, Tulane University
Oct 2017-present	Chief Technology Officer, the <i>BRAVO4Health LLC</i>
Sept 2017-JUL 2019	PE Fellow, Division of Diabetes Translation, CDC, USA
Aug 2012-August 2017	Research Assistant, Tulane University, USA
May 2014-August 2017	Senior Big-Data Analyst
May 2016-Sept 2016	Healthcare Informatics Consultant, Blue Cross and Blue Shield of Louisiana, USA
Jan 2011-June2012	Health Policy Consultant, Health Bureau of Jinan, China
Sep 2010-June 2012	Research Assistant, Shandong University, China
Sep 2009-January 2010	Clinical Intern, Transportation Hospital of Jinan, China
Jan 2010- June 2010	Healthcare Assistant, Community Health Center, Shandong, China

HONORS AND AWARDS

Conference/Competition

May 2019	Early Career Innovator Award	Centers for Disease Control and Prevention
Jun 2018	Travelling Grant	American Diabetes Association
Jan 2017	Honored Award	Patient Access Network (PAN) challenge
Jun 2016	Best Student Podium	ISPOR, Washington DC
Jun 2014	Best Student Poster	Academy Health Annual Research Meeting, San Diego
Feb 2013	Dean of the School of Public Health and Tropical Medicine Award	

Media Coverage:

Reported by *MedicalResearch*: Insulin Costs Rise But Mostly Not Paid For Out-of-Pocket by Patients.

Reported by *Medscape*: Implementing ACP Diabetes Guidelines Could Be Cost-Effective.

Reported by *MD Magazine*: ACP Guideline for A1c Levels Provide Cost-Effectiveness for Diabetics.

Reported by *Endocrinology Advisor*: Triple-Goal Achievement Reduces Risk for Complications in Type 2 Diabetes.

Reported in *Tulane News (2018)*: Tulane researchers develop new way to predict complications in diabetes patients.

Reported in *Tulane News (2016)* on presentation: The Costs of Supporting Safety-Net Transformation into Patient-Centered Medical Homes (PCMH) in Post-Katrina New Orleans

Reported in *ISPOR News (2015)* on paper: ENSURING THE FUTURE FOR CHINA'S ESSENTIAL DRUG POLICY.

Reported in *Tulane News (2015)* on research: Disparities in 30-Day Readmissions after Total Hip Arthroplasty.

TEACHING EXPERIENCES:

Course Co-Director

- *Intro to Pharmaceutical Outcomes and Policy* 2020 Spring
- *Patient Care 3- Asthma Module* 2019 Fall
- *2018 China National Health Technology Assessment Training* 2018 Summer
- GHMP-7740 *Economic evaluation and modelling* 2016 Fall, 2017 Fall, 2018 Fall
- ESCD -8410 *Advanced economic modelling* 2016 Fall

Guest Lectures:

- *"Application of Computer Simulation in Modern Clinical Practice."*
Provincial Diabetes Hospital, Shandong, China, 2018 Summer
- *"Intensive Glycemic Control is Less Cost Effective on older people with more comorbidities/ complications."*
Division of Diabetes Translation, CDC, 2017 Winter
- *"A Novel Risk Engine for Diabetes Progression and Mortality in the United States: Building, Relating, Acting, and Validating Outcomes (BRAVO)Model"*
School of Pharmacy, Purdue University, 2017 April
- *"PSM/PSW Application in Survey Design and Multiple Group Scenario"*
GHSD-8250 Advanced Research Methods, 2017 Spring
- *"PSM/PSW Application in Survey Design and Multiple Group Scenario"*
GHSD-8250 Advanced Research Methods, 2016 Spring
- *"Linear Model: from beginning to the infinity and beyond"*
GHSD-8250 Advanced Research Methods, 2016 Spring
- *"Decision Tree, Markov Model and TreeAge"*
GHSD-7740 Economic Evaluation and Modelling, 2015 Fall
- *"Discrete Event Modelling: basics and advanced application"*
GHSD-7740 Economic Evaluation and Modelling, 2015 Fall
- *"Alternative Method for Evaluating Observational Data: Propensity Score Matching"*

Teaching Assistant:

- *GHSD-8250 Advanced Research Methods* *2016 Spring*
- *GHSD-6450 Health Economics* *2015 Spring*
- *GHSD-7740 Economic Evaluation and Modeling* *2015 Fall*
- *GHSD-8250 Advanced Research Methods* *2015 Spring*

PEER-REVIEWED PUBLICATIONS

Published

1. Qin W, Xu L, Sun L, Jiajia Li, and **Shao H.** "Association between Frailty and Life Satisfaction among Older People in Shandong, China: The Differences in Age and General Self-Efficacy." *Psychogeriatrics*
2. Kristi A, Shao H, Shi L. "Policy Options for Addressing the High Cost of Specialty Pharmaceuticals." *Global Health Journal*
3. Kristin M, Zhuo X, Bardenheier B, **Shao H**, Laxy M, Schulze M. "Selecting the Optimal Risk Threshold of Diabetes Risk Scores to Identify High-Risk Individuals for Diabetes Prevention: A Cost-Effectiveness Analysis." *Acta Diabetologica*
4. **Shao H**, Lin J, Zhuo X, Rolka D, Greg E, Zhang P. (2019) Influence of Diabetes Complications on HbA1c Treatment Goals among Older US Adults: A Cost-Effectiveness Analysis. *Diabetes Care*, Epub Ahead
5. **Shao H**, Yang S, Fonseca V, Stoecker C, Shi L. (2019) Globalization Module for a Diabetes Progression Prediction Model The Building, Relating, Acting, and Validating Outcomes (BRAVO) Model. *Value in Health*. Epub ahead.
6. Shao, Y, **Shao, H**, Shi, L (2019) Serum uric acid as a risk factor of all-cause mortality and cardiovascular events among type 2 diabetes population: Meta-analysis of correlational evidence. *Journal of Diabetes and its Complications*. ePub ahead.
7. Qin, W, Xu, L., **Shao, H.** (2019) An Exploratory Spatial Analysis of Overweight and Obesity among Children and Adolescents in Shandong, China. *BMJ Open*. ePub ahead.
8. Hong, D, Shao, H, Shi, L. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists, Dipeptidyl Peptidase 4 (DPP-4) inhibitors: A Systematic Review. *Pharmacoeconomics* ePub ahead.
9. **Shao, H**, Yang, S, Fonseca V, Stoecker C, Shi L. (2019). " Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation." *Pharmacoeconomics* ePub ahead.
10. Mir, M.U., Akhtar F, **Shao H.** A Meta-analysis of the Association Between Needle Exchange Programs and HIV Seroconversion Among Injection Drug Users. *Cureus*, 2018. 10(9).
11. Qin W, Xu L, Li J, Sun L, **Shao H.** Xu N. Estimating Benefit Equity of Government Health Subsidy in Healthcare Services in Shandong Province, China: A Cross-sectional Study. *International Journal for Equity in Health* 17 (1): 61
12. **Shao, H.**, Fonseca V, Stoecker C, Shi L. (2018). "Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO)." *Pharmacoeconomics* ePub ahead.
13. Shi Q, **Shao H**, Shi L . Long-term Outcomes Associated with Triple-Goal Achievement in Veterans with Type 2 Diabetes Mellitus (T2DM). *American Journal of Managed Care*. ePub ahead.
14. **Shao H**, Charles S, Shuang Y, Shi L. The Pitfall of Instrumental Variables in Big Data: What the Rule of Thumb Can't Give You. *Communications in Statistics - Simulation and Computation*: epub ahead of time.
15. **Shao H**, Charles S, Shi L. Cost Sharing and Demand Elasticity on Disease Modifying Therapies (DMTs) in Multiple Sclerosis. *Value in Health*. Epub ahead of time.
16. Monnette A, Zhang Y, **Shao H.** Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review. *Pharmacoeconomics*. Epub ahead of time

17. Zawadzki N, **Shao H**, Shi L. Readmission Due To Infection Following Total Hip And Total Knee Procedures: A Retrospective Study. *Medicine*. 96(38): e7961
18. Shi Q, **Shao H**, Shi L. EVALUATION OF THE QUALITY BLUE PRIMARY CARE PROGRAM ON HEALTH OUTCOMES. *AJMC*. 2017;23(12):e402-e408.
19. Shi JZ, **Shao H**, Shi L. Direct Health Care Costs Associated with Obesity in Chinese Population in 2011. *Journal of Diabetes and Its Complications*. 2017;31(3):523-528.
20. **Shao H**, Zou D, Zhai S, Mohammed MU, Zawadzki NK, Shi Q, Liu S, Shi L. COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN VERSUS GLIMEPIRIDE AS MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CHINA. *Current Medical Research & Opinion*, 2017;33(2):359-369.
21. **Shao H**, Brown L, Diana M, Schmidt L, Mason K, Oronce CI, Shi L, Estimating the Costs of Supporting Safety-Net Transformation into Patient-Centered Medical Homes (PCMH) in Post-Katrina New Orleans. *Medicine*. 2016, 95(39): e4990.
22. **Shao H**, Mohammed MU, Thomas N, Babazadeh S, Yang S, Shi Q, Shi L. Evaluating Excessive Burden of Depression on Health Status and Health Care Utilization among Patients with Hypertension in a Nationally Representative Sample from the Medical Expenditure Panel Survey (MEPS 2012). *The Journal of Nervous and Mental Disease*. 2017;205(5):397-404.
23. Wu J, Li X, Song Y, **Shao H**, Shi Q, Qin D, et al. The impact of a bundled policy intervention on improving the performance of rural healthcare in China. *International Journal for Equity in Health*. 2016;15(1):1.
24. **Shao H**, Li S, Xu L, Yang S, Thomas NJ, Mir MU, et al. Mapping and Analyzing Stakeholders in China's Essential Drug System by Using a Circular Model: Who We Should Deal with Next? *Value in Health Regional Issues*. 2015;6:111-7.
25. Oronce CIA, **Shao H**, Shi L. Disparities in 30-Day Readmissions After Total Hip Arthroplasty. *Medical care*. 2015;53(11):924-30.
26. Velde N, Moparty K, Shi L, **Shao H**. Does an Inverse Correlation Exist between Vitamin D as Measured by 25-hydroxyvitamin D and PSA in Veterans with Prostate Cancer. *Med Surg Urol*. 2015;4(152):2.
27. Shi L, Liang F, **Shao H**, Hu X, Gu Q, Liu W, et al. Preliminary development of a reference conceptual framework about social responsibility of public hospitals in China. *Journal of Hospital Administration*. 2015;4(2):p23.
28. Katalenich B, Shi L, Liu S, **Shao H**, McDuffie R, Carpio G, et al. Evaluation of a remote monitoring system for diabetes control. *Clinical therapeutics*. 2015;37(6):1216-25.
29. Deng J, Gu S, **Shao H**, Dong H, Zou D, Shi L. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. *Journal of medical economics*. 2015;18(11):974-89.
30. Shi L, **Shao H**, Zhao Y, Thomas NA. Is hypoglycemia fear independently associated with health-related quality of life? *Health and quality of life outcomes*. 2014;12(1):1.
31. **Shao H**, S L, Lingzhong Xu, Shuang Yang. Analyzing the Factors in Influence Grassroots Doctors' willingness of using Essential Drugs in Shandong Province. *China Healthcare Administration*. 2012:904-6.
32. **Shao H**, S L, Lingzhong Xu, Bo Ning, Shuang Yang. Impact of Essential Drug Policy on Medicine Purchasing Propensity in Urban Residents. *Medicine&Philosophy*. 2012;33(6):46-8.
33. Shuang Yang LX, Xingzhou Wang, **Shao H**, Qingyun Xue, Zhen Guo, Weining Zhao, Qian Zhang, Rongfei Xu. Analysis on satisfactory degree of essential drug policies among outpatients. *Journal of Shandong University*. 2012;50(9):124.
34. Shuang Yang LX, Xingzhou Wang, **Shao H**. Analyzing the Awareness and Affecting Factors of Essential Medicines among Rural Residents in Shandong Province. *Medicine&philosophy*. 2012;33(2):53-4.
35. **Shao H**, S L, Lingzhong Xu, Shuang Yang. The Study on Tobacco Addiction and Its Correlation Factors in Rural Dongying. *Medicine&Philosophy*. 2011;32(10):37-9.
36. Bo Ning SL, **Shao H**. Analyzing the Factors in Influence Grassroots Doctors' willingness of using Essential Drugs in Shandong Province. *China Economics*. 2012;31(1):29.
37. Shuang Yang LX, Xingzhou Wang, **Shao H**, Qingyun Xue, Zhen Guo, Weining Zhao, Qian Zhang, Rongfei Xu. Cross-sectional study on implementation of essential drug system in community health services centers in Shandong Province. *China Healthcare Administration*. 2011:891-2.

Research Letters

1. **Shao H**, Shi L, Fonseca V. Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. *Diabetes Care* 2019;42:2298-2306

Manuscripts under Review:

1. Zhou XL, Shao H, Greg E, Zhang P. What Has Contributed to the Increase in the National Spending on Antidiabetic Drugs: 2005-2016? The 79th annual conference of American Diabetes Association. June 6-12 in San Francisco.
2. Qin W, Xu L, Li J, Sun L, Shao H. Frailty and Life Satisfaction among Elderly People in Shandong, China: The Roles of Age and General Self-efficacy
3. Allaire, B. Shao H. A model to assess the costs and consequences of population-wide food and nutrition policies: the Microsimulation of Nutrition, Diabetes, and Cardiovascular Disease (MONDAC)

Manuscript in Development:

1. Shao H, Shi L, Charles S. The Individualized Treatment Plan (ITP)—an End to Linear Model Era
2. Shao H, Greg E, Zhang P. Trends in Total and Out-of-Pocket Payment on a Yearly Insulin Supply among Private Health Insured U.S. Adults with Diabetes from 2003 to 2016
3. Shao H, Greg E, Zhang P. Cost Effectiveness of the New 2018 ACP Glycemic Control Guideline among U.S. Adults with Type 2 Diabetes.
4. Shao H, Greg E, Zhang P. Trend in Total Payment and Out-of-Pocket Payment on a Yearly Supply of Oral Antidiabetic Drug Types among U.S. Adults with Private Health Insurance from 2003 to 2016.

Conference Podium Presentations (Presenting Author Underlined):

1. Shao H, Greg E, Zhang P. Trends in Total and Out-of-Pocket Payment on a Yearly Insulin Supply among Private Health Insured U.S. Adults with Diabetes from 2003 to 2016. The 79th annual conference of American Diabetes Association. June 6-12 in San Francisco.
2. Shao H, Greg E, Zhang P. Cost Effectiveness of the New 2018 ACP Glycemic Control Guideline among U.S. Adults with Type 2 Diabetes. The 79th annual conference of American Diabetes Association. June 6-12 in San Francisco.
3. Zhou XL, Shao H, Greg E, Zhang P. What Has Contributed to the Increase in the National Spending on Antidiabetic Drugs: 2005-2016? The 79th annual conference of American Diabetes Association. June 6-12 in San Francisco.
4. Shao H, Zhang P. Simulation Results of CDC-RTI model and its implication on Treatment Superiority. The 9th Mount Hood Challenge Meeting, OCT 4-8, 2018 in Düsseldorf, German.
5. Shi L, Shao H, Yang S, Fonseca V. Estimating Quality of Life Decrements Due to Diabetes Complications in the United States. The 9th Mount Hood Challenge Meeting, OCT 4-8, 2018 in Düsseldorf, German.
6. Shao H, Lin J, Zhuo X, Laxy M, Gregg E, Zhang P. Influence of Diabetes Complications on the Cost-effectiveness of HbA1c Treatment Goals in Older US Adults. CDC Annual Science Day. The 78th annual conference of American Diabetes Association. June 22-26 in Orlando.
7. Laxy M, Gregg E, Shao H, Zhang P. Cost-effectiveness of structured lifestyle programs for diabetes prevention in the Medicaid population. The 78th annual conference of American Diabetes Association. June 22-26 in Orlando.
8. Shao H, S, Laxy M, Gregg E, Zhang P. New 2017 ACCAHA hypertension guidelines cost-effectiveness among US adults with type 2 diabetes. The 78th annual conference of American Diabetes Association. June 22-26 in Orlando.
9. Shao H, Shrestha S, Laxy M, Gregg E, Zhang P. Program Selections for Type 2 Diabetes Prevention: a Cost-effectiveness Analysis. CDC Annual Science Day. June 2018 in Atlanta.
10. Shao H, Shrestha S, Laxy M, Gregg E, Zhang P. Trend in Out-of-pocket Payments for Antidiabetic Medications among US Adults with Private Health Insurance from 2003 to 2016: A Combined Recursive Partition Interrupted Time Series Analysis, CDC Annual Science Day. June 2018 in Atlanta.
11. Shao H, Lin J, Zhuo X, Laxy M, Gregg E, Zhang P. Influence of Diabetes Complications on the Cost-effectiveness of HbA1c Treatment Goals in Older US Adults. CDC Annual Science Day. June 2018 in Atlanta.
12. Shao H, Laxy M, Gregg E, Zhang P. New 2017 ACCAHA hypertension guidelines cost-effectiveness among US adults with type 2 diabetes Final. CDC Annual Science Day. June 2018 in Atlanta.

13. **Shao H**, Shi L, Globalization Module for a Diabetes Progression Prediction Model: the BRAVO model. *ISPOR 23rd Annual International Meeting*, May 19-23, 2018 in Baltimore, USA.
14. **Shao H**, Fonseca V, Stoecker C, Shi L. UPDATING RISK ENGINE FOR DIABETES PROGRESSION AND MORTALITY IN THE UNITED STATES: the Building, Relating, Acting, Validating for Outcomes (BRAVO) of Diabetes Risk Engine. Annual Meeting of International Health Economics Association, July 7-11, 2017 in Boston, US.
15. **Shao H**, Stoecker C, Shi L. When Doubly Robust Is Not Robust Enough: Nonparametric Matching Methods Under Treatment Heterogeneity. Academy Health Annual Research Meeting, June, 2017 in New Orleans.
16. **Shao H**, Shi L, Diana M, Brown L, Mason K, Cocran D, Carruth A, Schmidt L, Estimating the Costs of Supporting Safety-Net Transformation into Patient-Centered Medical Homes (PCMH) in Post-Katrina New Orleans. *ISPOR 21st Annual International Meeting*, May 21-25, 2016 in DC, USA
17. **Shao H**, Shi L. Size Distortion of Hypothesis Test for Two-Stage Least Squares Model: What the Gold Standard Can't Give You. *The CES 2015 North America Conference*, March 13-14, 2015 in Ann Arbor, Michigan, USA

Poster Presentations:

1. **Shao H**, Shi L, Furman R, Fonseca V. Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications. The 79th annual conference of American Diabetes Association. June 6-12 in San Francisco.
2. **Shao H**, Greg E, Zhang P. Trend in Total Payment and Out-of-Pocket Payment on a Yearly Supply of Oral Antidiabetic Drug Types among U.S. Adults with Private Health Insurance from 2003 to 2016. The 79th annual conference of American Diabetes Association. June 6-12 in San Francisco.
3. **Shao H**, Shi L, Fonseca V. Estimating Diabetes Duration from Electronic Medical Records (EMRs) with an Intrinsic Diabetes Risk Prediction Model: From Clinical Trial to Real-World Clinical Practice. The 79th annual conference of American Diabetes Association. June 6-12 in San Francisco.
4. **Shao H**, Fonseca V, Shi L. Is higher-priced insulin associated with better economic and health outcomes? a study from a value-based payment perspective. ISPOR. May 18-22 in New Orleans.
5. **Shao H**, Fonseca V, Stoecker C, Shi L. Projecting Long-Term Diabetes Complications through a BRAVO-Based Mock Simulation for Promoting Diabetes Prevention Program (DPP). The 78th annual conference of American Diabetes Association. June 22-26 in Orlando.
6. Shao Y, **Shao H**, Shi L. Serum Uric Acid (SUA) as a Risk Factor of Cardiovascular Events in Diabetes Population: a Meta-analysis of Correlational Evidence. The 78th annual conference of American Diabetes Association. June 22-26 in Orlando.
7. **Laxy M**, Gregg E, **Shao H**, Zhang P. Health Benefits and Cost Impact of Paying for Diabetes Prevention Lifestyle Programs in Medicaid Beneficiaries. Academy Health Annual Research Meeting. June 22-26 2018 in Seattle.
8. **Laxy M**, Gregg E, **Shao H**, Zhang P. The impact of insurance status on quality of diabetes care in the United States. Academy Health Annual Research Meeting. June 22-26 2018 in Seattle
9. **Shao H**, Shrestha S, Laxy M, Gregg E, Zhang P. Program Selections for Type 2 Diabetes Prevention: a Cost-effectiveness Analysis. Academy Health Annual Research Meeting. June 22-26 2018 in Seattle.
10. **Shao H**, Shrestha S, Laxy M, Gregg E, Zhang P. Trend in Out-of-pocket Payments for Antidiabetic Medications among US Adults with Private Health Insurance from 2003 to 2016: A Combined Recursive Partition Interrupted Time Series Analysis, Academy Health Annual Research Meeting. June 22-26 2018 in Seattle.
11. **Shao H**, Yang S, Fonseca V, Shi L. Estimating Quality of Life Decrements Due to Diabetes Complications in the United States. ISPOR 23rd Annual International Meeting, May 19-23, 2018 in Baltimore, US.
12. **Shao H**, Shi L. THE IMPACT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND METHICILLIN-SENSITIVE STAPHYLOCOCCUS AUREUS (MSSA) INFECTION ON HOSPITAL READMISSIONS AMONG PATIENTS WITH PNEUMONIA. ISPOR 22nd Annual International Meeting, May 21-25, 2017 in Boston, US.
13. **Yin L**, **Shao H**, Shi L. REGIONAL VARIATION OF INTRAVENOUS TISSUE PLASMINOGEN ACTIVATOR (IV TPA) UTILIZATION AMONG ISCHEMIC STROKE PATIENTS IN THE UNITED STATES (US). Academy Health Annual Research Meeting, June, 2017 in New Orleans.

14. **Shao H**, Fonseca V, Stoecker C, Shi L. UPDATING RISK ENGINE FOR DIABETES PROGRESSION AND MORTALITY IN THE UNITED STATES: INTERNAL VALIDATION. ISPOR 22st Annual International Meeting, May 21-25, 2017 in Boston, US.
15. **Shao H**, Stoecker C, Shi L. When Doubly Robust Is Not Robust Enough: Nonparametric Matching Methods Under Treatment Heterogeneity. ISPOR 22st Annual International Meeting, May 21-25, 2017 in Boston, US.
16. **Shao H**, Qian Shi, Shuqian Liu, Lizheng Shi. COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN VERSUS GLIMEPIRIDE AS MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CHINA. The ISPOR 7th Asia-Pacific Conference. Sept 3-6, 2016 in Singapore.
17. Shuyan G, **Shao H**, Hengjin Dong. COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA. The ISPOR 7th Asia-Pacific Conference. Sept 3-6, 2016 in Singapore. Sept 3-6, 2016 in Singapore.
18. **Velde N**, Moparty K, Shi L, **Sha H**. Does an Inverse Correlation Exist Between Vitamin D as Measured by 25(OH) Choleciferol and PSA in Veterans with Prostate Cancer, Louisiana Cancer Research Consortium, April 22, 2016 in New Orleans, USA
19. **Shao H**, Shi L, Charles S. Cost Sharing and Demand Elasticity on Disease Modifying Therapies (DMTs) in Multiple Sclerosis. ISPOR 21st Annual International Meeting, May 21-25, 2016 in DC, USA
20. **Shao H**, Mir MU, Ye X, Thomas N, Babazadeh S. Impact of Depression on Health Status and Health Care Utilization in Patient with Hypertension. ISPOR 21st Annual International Meeting, May 21-25, 2016 in DC, USA
21. Michele S, Liu E, Wang Y, **Shao H**, Shi L. READMISSION DUE TO INFECTION FOLLOWING TOTAL HIP AND TOTAL KNEE PROCEDURES. ISPOR 21st Annual International Meeting, May 21-25, 2016 in DC, USA
22. **Shao H**, Shi L. Effect of health insurance benefit plan design on comparative effectiveness of anti-diabetic medications in adults with type 2 diabetes mellitus. American Society of Health Economics Fifth Biennial Conference, June, 2014 in Los Angeles.
23. **Shao H**, Shi L, Shi Q. Size distortion of hypothesis tests for two-stage least squares model: what the rule of thumb can't give you. ISPOR 19th Annual International Meeting, June, 2014 in Montreal, QC, Canada.
24. **Oronce CI**, **Shao H**, Shi L. Disparities in 30-day readmissions after total hip arthroplasty. Academy Health Annual Research Meeting, June, 2014 in San Diego.
25. Katalenich B, Shi L, Liu S, **Shao H**, McDuffie R, Hagggar M, Wang A, Carpio G, Thethi, Fonseca V. Evaluation of a remote monitoring system for diabetes control and medication adherence. The 74th American Diabetes Association annual meeting. June, 2014 in San Francisco.
26. Price-Haywood EG, Amering S, **Shao H**, Shi L. Diabetes care management: comparative effectiveness of clinical decision support vs. additional pharmacist-led self-management support. American Public Health Association. Annual Conference. November 2014 in New Orleans.
27. **Shao H**, Shi L. Interventions for reducing 30-day hospital readmission: A systematic review. Academy Health Annual Research Meeting, June, 2013 in Baltimore.
28. **Shao H**, Shi L. Mapping and analyzing stakeholders in china's essential drug operation system by using circular model: who we should deal with next? ISPOR 18th Annual International Meeting, June, 2013 in New Orleans.
29. Shi L, **Shao H**, Is hypoglycemia fear independently associated with health-related quality of life? ISPOR 18th Annual International Meeting, June, 2013 in New Orleans.
30. **Shao H**, Shi L, Mapping and Analyzing Stakeholders in China's Essential Drug System by Using a Circular Model: Who We Should Deal with Next? Tulane Health Research Science Day, Feb 1-2, 2013 in New Orleans, USA

Grants and Contracts

Project Title: Diabetes Risk Prediction Model: A Demonstration Project using Electronic Medical Records and Insurance Claims. Funded by OCHSNER Health System.

Role: Investigator

Project Title: Impact of a CMS Reimbursement Policy Supporting Care Coordination in Louisiana. (March 2016- February 2021). Funded by Patient Centered Outcomes Research Institute (PCORI)

Role: proposal writing, data analyst

Project Title: Constructing risk stratification model for hospital readmission, linking HER data to claims data. (March 2016- May 2017). Submitted to Patient Centered Outcomes Research Institute (PCORI)

Role: proposal writing

Project Title: Evaluating the cost-effectiveness of Dapagliflozin comparing to Glimepiride and Acarbose, using CARDIFF diabetes model (Jan 2015- Jan 2016). Funded by Astra Zeneca.

Role: proposal writing, investigator

Project Title: Demand elasticity for Disease-Modifying-Treatments (DMTs) among Multiple Sclerosis patients. Submitted to the Society of Multiple Sclerosis.

Role: proposal writing

Project Title: Prevalence trend and the Associated Health Services Utilizations and Costs of Methicillin-resistant Staphylococcus aureus (MRSA) Infection among Hospitalized Patients (Apr 2014-Jan 2015). Founded by Cepheid.

Role: proposal writing, data analyst

Project Title: Estimating the Costs of Supporting Safety-Net Transformation into Patient-Centered Medical Homes in Post-Katrina New Orleans (Sept 2014-June 2015). Funded by Patient Centered Outcomes Research Institute (PCORI).

Role: data analyst

Service to the Profession

Reviewers

I actively involved in reviewing pre-publication reviews for the following journals:

Diabetes Care

Value in Health

PLOS ONE

Journal of Medical Economics

Drugs & Aging

Medical Economics

International Journal of Physical Medicine and Rehabilitation

Value in Health Regional Issues

Journal of Diabetes and Its Complications

Professional Associations

Member of Editorial board for the Global Health Journal

Member of Editorial board for the Journal of Diabetes Mellitus and Metabolic Syndrome

Member of Editorial board for the JENPUB Diabetes & Endocrine Disorders

President of Tulane Student Chapter for International Society for Pharmacoeconomics and Outcomes Research (ISPOR) *June 2013 – May 2017*

Member of Grant Objective Review Committee for the Division of Population Health, CDC *Feb 2018*

Member of Grant Objective Review Committee for the Division of Diabetes Translation, CDC *Feb 2018*

Member of Health Economics Research Group (HERG) award committee, CDC *OCT 2017*

Members, International Society for Pharmacoepidemiology (ISPE)

Members, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Members, American Society of Health Economics (ASHEcon)

Members, Chinese Economists Society (CES)

Members, American Diabetes Association (ADA)

Members, Academy Health

Members, International Health Economics Association (iHEA)

KEY SKILLS:

- Policy Impact Evaluation and comparative effectiveness analysis
- Advanced Econometrics
- Cost-effectiveness Evaluation, Cost-benefit Analysis, Cost Minimization analysis and Budget Impact analysis
- Senior Data Analyst, experienced in working with large databases (e.g. MarketScan, HCUP, MEPS, LaCDRN, MPCD, NHANES, VA, CHARLES, ACCORD)
- Markov Model, Discrete Event model and Decision Tree
- Senior programmer, SAS, Stata, R, SPSS, TREEAGE, VBA, C++ and SQL
- Epidemiologic Research Methods (Experimental, Quasi-Experimental, & Complex Survey Designs)
- Data mining and Computer Simulation
- Bayesian Inference
- Stakeholder Analysis